ONCOSIL MEDICAL LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0130 AUD | 0.00% |
|
+8.33% | +44.44% |
| Aug. 30 | OncoSil Medical Limited Appoints Peter Hall as Non-Executive Director | CI |
| Aug. 30 | OncoSil Medical Limited Reports Earnings Results for the Full Year Ended June 30, 2024 | CI |
Company Valuation: OncoSil Medical Limited
| Fiscal Period: Junio | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 143.6 | 33.43 | 95.29 | 42.26 | 39.65 | 23.71 |
| Change | - | -76.72% | 185.06% | -55.65% | -6.18% | -40.2% |
| Enterprise Value (EV) 1 | 128.4 | 25.74 | 74.4 | 30.5 | 28.67 | 14.49 |
| Change | - | -79.95% | 189.07% | -59% | -6% | -49.47% |
| P/E ratio | -13.9x | -3.89x | -17.7x | -4.14x | -3.02x | -1.2x |
| PBR | 7.91x | 3.13x | 4.35x | 3.61x | 3.55x | 2.4x |
| PEG | - | 0.2x | 0.3x | -0x | -0.9x | 0x |
| Capitalization / Revenue | 32.3x | 9.22x | 34.5x | 32.5x | 37.3x | 16.2x |
| EV / Revenue | 28.9x | 7.1x | 26.9x | 23.5x | 27x | 9.87x |
| EV / EBITDA | -14.9x | -2.94x | -16.8x | -2.9x | -2.72x | -1.28x |
| EV / EBIT | -14.9x | -2.93x | -16.7x | -2.89x | -2.71x | -1.28x |
| EV / FCF | -24.5x | -5.86x | -24.8x | -5.93x | -4.55x | -2.03x |
| FCF Yield | -4.08% | -17.1% | -4.03% | -16.9% | -22% | -49.3% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -0.0166 | -0.0136 | -0.006499 | -0.0128 | -0.0132 | -0.01 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 4.448 | 3.626 | 2.764 | 1.298 | 1.063 | 1.467 |
| EBITDA 1 | -8.601 | -8.747 | -4.419 | -10.51 | -10.55 | -11.32 |
| EBIT 1 | -8.641 | -8.786 | -4.446 | -10.54 | -10.58 | -11.34 |
| Net income 1 | -8.54 | -8.567 | -4.262 | -10.43 | -10.73 | -11.34 |
| Net Debt 1 | -15.21 | -7.689 | -20.89 | -11.76 | -10.98 | -9.223 |
| Reference price 2 | 0.2300 | 0.0530 | 0.1150 | 0.0530 | 0.0400 | 0.0120 |
| Nbr of stocks (in thousands) | 624,159 | 630,709 | 828,601 | 797,343 | 991,242 | 1,975,841 |
| Announcement Date | 8/22/18 | 8/22/19 | 8/19/20 | 8/18/21 | 8/30/22 | 8/31/23 |
1AUD in Million2AUD
Estimates
| P/E ratio | EV / Sales | EV / EBITDA | Yield (Y) | Capi. ($) | ||
|---|---|---|---|---|---|---|
| 58.18x | 18.04x | 43.81x | +0.58% | 813B | ||
| 38.81x | 13.49x | 27.47x | +1.29% | 582B | ||
| 21.05x | 4.55x | 12.91x | +2.85% | 396B | ||
| 37.64x | 7.13x | 15.41x | +3.22% | 342B | ||
| 15.71x | 4.99x | 11.43x | +2.61% | 299B | ||
| 16.36x | 3.88x | 10.15x | +3.59% | 262B | ||
| 29.75x | 5.34x | 15.82x | +1.85% | 258B | ||
| 21.17x | 5.01x | 12.68x | +3.22% | 237B | ||
| 48.68x | 6.7x | 11.8x | +2.86% | 172B | ||
| Average | 31.93x | 7.68x | 17.94x | +2.45% | 373.35B | |
| Weighted average by Cap. | 36.04x | 9.81x | 22.96x | +2.05% |
Year-on-year evolution of the PER
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- OSL Stock
- Valuation OncoSil Medical Limited